Legend Biotech Corporation
HealthcareNASDAQ:LEGN · NASDAQ Global Select
-$0.26 today
Vol 1.70M · Avg 2.37M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$1.1B of revenue converted into -$250.2M of net income for the selected period. Gross margin is 55.3% and net margin is -22.9%, showing how much revenue survives after costs and taxes. EPS is $-1.37, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B +64.0% | $627.2M +120.0% | $285.1M +143.7% | $117.0M +70.0% | $68.8M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $408.1M +74.0% | $234.6M +62.7% | $144.2M +120.6% | $65.4M | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $620.8M +58.1% | $392.7M +178.6% | $140.9M +172.9% | $51.6M -25.0% | $68.8M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 60.3% -2.3pp | 62.6% +13.2pp | 49.4% +5.3pp | 44.1% -55.9pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $414.7M +0.3% | $413.5M +8.2% | $382.2M +13.9% | $335.6M +7.1% | $313.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $341.6M +20.2% | $284.3M +41.5% | $200.9M +15.4% | $174.0M +16.4% | $149.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $757.3M +8.8% | $695.9M +19.9% | $580.4M +14.4% | $507.3M +10.0% | $461.1M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $28.9M +23.7% | $23.4M +14.2% | $20.5M +11.2% | $18.4M +32.2% | $13.9M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$232.3M -105.3% | -$113.2M +76.3% | -$477.9M -14.7% | -$416.5M -6.2% | -$392.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -22.6% -4.5pp | -18.0% +149.5pp | -167.6% +188.4pp | -356.0% +214.1pp | -570.1% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$136.5M +55.0% | -$303.2M +31.0% | -$439.5M +3.5% | -$455.6M -16.1% | -$392.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -13.3% +35.1pp | -48.3% +105.8pp | -154.1% +235.3pp | -389.4% +180.6pp | -570.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $40.1M -34.5% | $61.2M +12.3% | $54.5M +565.9% | $8.2M +742.6% | $971.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $21.4M -1.0% | $21.6M -0.8% | $21.8M +101.9% | $10.8M +1099.6% | $900.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$146.1M -200.7% | $145.1M +280.0% | -$80.6M -914.8% | $9.9M +166.4% | -$14.9M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$282.6M -78.7% | -$158.1M +69.6% | -$520.1M -16.7% | -$445.7M -9.5% | -$407.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -27.5% -2.3pp | -25.2% +157.2pp | -182.4% +198.5pp | -380.9% +210.7pp | -591.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $14.2M -24.8% | $18.9M +1113.6% | -$1.9M -398.2% | $625.0K +117.3% | -$3.6M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$296.8M -67.7% | -$177.0M +65.8% | -$518.3M -16.1% | -$446.3M -10.6% | -$403.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | -28.8% -0.6pp | -28.2% +153.5pp | -181.8% +199.7pp | -381.5% +204.9pp | -586.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 -64.9% | -$1 +67.0% | -$3 -4.6% | -$3 -2.6% | -$3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 -64.9% | -$1 +67.0% | -$3 -4.6% | -$3 -2.6% | -$3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $184.3M +0.8% | $182.9M +3.8% | $176.1M +10.7% | $159.0M +12.9% | $140.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $184.3M +0.8% | $182.9M +3.8% | $176.1M +10.7% | $159.0M +12.9% | $140.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.33B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.28B
Celcuity Inc.
NASDAQ:CELC
$4.33B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.12B
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
$2.80B
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
$2.66B
Disc Medicine, Inc.
NASDAQ:IRON
$2.61B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.55B
Zai Lab Limited
NASDAQ:ZLAB
$1.92B
Ascentage Pharma Group International
NASDAQ:AAPG
$414.85M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does LEGN generate?
Legend Biotech Corporation (LEGN) reported $1.03B of revenue in fiscal 2025.
Is LEGN profitable?
Legend Biotech Corporation (LEGN) reported -$296,800,000.00 of net income, with a net margin of -28.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.